Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/13492
Title: A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures.
Authors: Beran, R G;Berkovic, Samuel F;Buchanan, N;Danta, G;Mackenzie, R;Schapel, G;Sheean, G;Vajda, F
Affiliation: Austin Hospital, Heidelberg, Victoria, Australia.
Issue Date: 1-Dec-1996
Citation: Seizure; 5(4): 259-65
Abstract: The efficacy and tolerability of vigabatrin as add-on therapy was assessed in patients with uncontrolled partial seizures. Ninety-seven patients entered this seven-centre, double-blind, placebo-crossover study. Vigabatrin (2 g or 3 g) or placebo was administered daily. Vigabatrin was well-tolerated and did not cause clinically significant adverse drug effects when added to established anticonvulsant therapy. No significant differences were observed between dose groups for the overall incidence of adverse events, although drowsiness and visual disturbances (diplopia, ataxia, visual abnormalities) showed a dose-related increase with vigabatrin treatment. The results of this study indicate that vigabatrin, given in a daily dose of either 2 g or 3 g is significantly more effective than placebo in reducing seizure frequency among patients with partial seizures.
Internal ID Number: 8952010
URI: http://ahro.austin.org.au/austinjspui/handle/1/13492
URL: http://www.ncbi.nlm.nih.gov/pubmed/8952010
Type: Journal Article
Subjects: Adolescent
Adult
Aged
Anticonvulsants.administration & dosage.adverse effects
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Electroencephalography.drug effects
Epilepsy, Complex Partial.drug therapy
Female
Humans
Male
Middle Aged
Treatment Outcome
Vigabatrin
gamma-Aminobutyric Acid.administration & dosage.adverse effects.analogs & derivatives
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.